MALAT-1 Is a Key Regulator of Epithelial-Mesenchymal Transition in Cancer: A Potential Therapeutic Target for Metastasis

被引:4
|
作者
Hussein, Mohamed Ali [1 ,2 ]
Valinezhad, Kamyab [3 ]
Adel, Eman [2 ]
Munirathinam, Gnanasekar [3 ]
机构
[1] Childrens Canc Hosp Egypt, Dept Pharmaceut Serv, Cairo 57357, Egypt
[2] Amer Univ Cairo, Sch Sci & Engn, Dept Biol, New Cairo 11835, Egypt
[3] Univ Illinois, Coll Med, Dept Biomed Sci, Rockford, IL 61107 USA
关键词
MALAT-1; EMT; metastasis; chemoresistance; microRNA; lncRNA; NONCODING RNA MALAT1; SQUAMOUS-CELL CARCINOMA; LNCRNA MALAT1; GASTRIC-CANCER; CISPLATIN RESISTANCE; CERVICAL-CANCER; RHO-GTPASES; HEPATOCELLULAR-CARCINOMA; LUNG ADENOCARCINOMA; SIGNALING PATHWAY;
D O I
10.3390/cancers16010234
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Metastasis-associated lung adenocarcinoma transcript-1 (MALAT-1) is overexpressed in several cancers and exerts its effect by controlling gene expression and stimulating cell proliferation, migration, and metastasis and playing a dynamic role in mediating the epithelial-to-mesenchymal transition (EMT), which leads to the acquisition of stem cell-like properties and chemoresistance. MALAT-1 modulates EMT by interacting with various intracellular signaling pathways, including phosphoinositide 3-kinase (PI3K)/Akt and Wnt/beta-catenin. It also sponges microRNAs, consequently increasing the gene expression of several essential genes regulating cancer progression and metastasis, rendering it a good candidate for therapeutic intervention. Several innovative approaches have been exploited to target MALAT-1, such as short hairpin RNAs (shRNAs), antisense oligonucleotides (ASOs), and natural products.Abstract Metastasis-associated lung adenocarcinoma transcript-1 (MALAT-1) is a long intergenic non-coding RNA (lncRNA) located on chr11q13. It is overexpressed in several cancers and controls gene expression through chromatin modification, transcriptional regulation, and post-transcriptional regulation. Importantly, MALAT-1 stimulates cell proliferation, migration, and metastasis and serves a vital role in driving the epithelial-to-mesenchymal transition (EMT), subsequently acquiring cancer stem cell-like properties and developing drug resistance. MALAT-1 modulates EMT by interacting with various intracellular signaling pathways, notably the phosphoinositide 3-kinase (PI3K)/Akt and Wnt/beta-catenin pathways. It also behaves like a sponge for microRNAs, preventing their interaction with target genes and promoting EMT. In addition, we have used bioinformatics online tools to highlight the disparities in the expression of MALAT-1 between normal and cancer samples using data from The Cancer Genome Atlas (TCGA). Furthermore, the intricate interplay of MALAT-1 with several essential targets of cancer progression and metastasis renders it a good candidate for therapeutic interventions. Several innovative approaches have been exploited to target MALAT-1, such as short hairpin RNAs (shRNAs), antisense oligonucleotides (ASOs), and natural products. This review emphasizes the interplay between MALAT-1 and EMT in modulating cancer metastasis, stemness, and chemoresistance in different cancers.
引用
下载
收藏
页数:22
相关论文
共 50 条
  • [1] Epithelial-mesenchymal transition as a target for botanicals in cancer metastasis
    Salehi, Bahare
    Varoni, Elena Maria
    Sharifi-Rad, Mehdi
    Rajabi, Sadegh
    Zucca, Paolo
    Iriti, Marcello
    Sharifi-Rad, Javad
    PHYTOMEDICINE, 2019, 55 : 125 - 136
  • [2] Cancer Stemness/Epithelial-Mesenchymal Transition Axis Influences Metastasis and Castration Resistance in Prostate Cancer: Potential Therapeutic Target
    Castellon, Enrique A.
    Indo, Sebastian
    Contreras, Hector R.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (23)
  • [3] The therapeutic potential of targeting the epithelial-mesenchymal transition in cancer
    Ginnebaugh, Kevin R.
    Ahmad, Aamir
    Sarkar, Fazlul H.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2014, 18 (07) : 731 - 745
  • [4] Editorial: Epithelial-mesenchymal transition (EMT) as a therapeutic target in cancer
    Zhong, Weilong
    Sun, Tao
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [5] Epithelial-Mesenchymal Transition (EMT) as a Therapeutic Target
    Jonckheere, Sven
    Adams, Jamie
    De Groote, Dominic
    Campbell, Kyra
    Berx, Geert
    Goossens, Steven
    CELLS TISSUES ORGANS, 2022, 211 (02) : 157 - 182
  • [6] Long noncoding RNA MALAT-1: A versatile regulator in cancer progression, metastasis, immunity, and therapeutic resistance
    Xu, Dexin
    Wang, Wenhai
    Wang, Duo
    Ding, Jian
    Zhou, Yunan
    Zhang, Wenbin
    NON-CODING RNA RESEARCH, 2024, 9 (02): : 388 - 406
  • [7] Epithelial-mesenchymal transition as a therapeutic target for overcoming chemoresistance in pancreatic cancer
    Elaskalani, Omar
    Razak, Norbaini Binti Abdol
    Falasca, Marco
    Metharom, Pat
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2017, 9 (01) : 37 - 41
  • [8] Epithelial-mesenchymal transition as a therapeutic target for overcoming chemoresistance in pancreatic cancer
    Omar Elaskalani
    Norbaini Binti Abdol Razak
    Marco Falasca
    Pat Metharom
    World Journal of Gastrointestinal Oncology, 2017, (01) : 37 - 41
  • [9] CtBP1 is involved in epithelial-mesenchymal transition and is a potential therapeutic target for hepatocellular carcinoma
    Zhang, Xiao-Ling
    Huang, Cheng-Xin
    Zhang, Jie
    Inoue, Akira
    Zeng, Si-En
    Xiao, Sheng-Jun
    ONCOLOGY REPORTS, 2013, 30 (02) : 809 - 814
  • [10] SLUG is a key regulator of epithelial-mesenchymal transition in pleomorphic adenoma
    Kim, Hyesung
    Lee, Seung Bum
    Myung, Jae Kyung
    Park, Jeong Hwan
    Park, Eunsun
    Kim, Dong Il
    Lee, Cheol
    Kim, Younghoon
    Park, Chul-Min
    Kim, Min Bum
    Lim, Gil Chai
    Jang, Bogun
    LABORATORY INVESTIGATION, 2022, 102 (06) : 631 - 640